vs
Emerald Holding, Inc.（EEX）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
Emerald Holding, Inc.的季度营收约是再鼎医药的1.0倍（$132.7M vs $127.1M），Emerald Holding, Inc.同比增速更快（24.3% vs 17.1%），Emerald Holding, Inc.自由现金流更多（$11.7M vs $-26.7M），过去两年再鼎医药的营收复合增速更高（20.8% vs -0.3%）
TVS Emerald Haven地产有限公司是一家印度房地产开发企业，总部位于泰米尔纳德邦金奈，为TVS控股旗下子公司，专注于打造可持续居住社区以及各类城市开发项目，在印度本土房地产业务领域拥有清晰的业务定位。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
EEX vs ZLAB — 直观对比
营收规模更大
EEX
是对方的1.0倍
$127.1M
营收增速更快
EEX
高出7.1%
17.1%
自由现金流更多
EEX
多$38.4M
$-26.7M
两年增速更快
ZLAB
近两年复合增速
-0.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $132.7M | $127.1M |
| 净利润 | $-30.2M | — |
| 毛利率 | — | 51.0% |
| 营业利润率 | -11.8% | -54.6% |
| 净利率 | -22.8% | — |
| 营收同比 | 24.3% | 17.1% |
| 净利润同比 | -692.2% | — |
| 每股收益（稀释后） | $-0.15 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EEXZLAB
| Q4 25 | $132.7M | $127.1M | ||
| Q3 25 | $77.5M | $115.4M | ||
| Q2 25 | $105.5M | $109.1M | ||
| Q1 25 | $147.7M | $105.7M | ||
| Q4 24 | $106.8M | $108.5M | ||
| Q3 24 | $72.6M | $101.8M | ||
| Q2 24 | $86.0M | $100.1M | ||
| Q1 24 | $133.4M | $87.1M |
净利润EEXZLAB
| Q4 25 | $-30.2M | — | ||
| Q3 25 | $-14.4M | $-36.0M | ||
| Q2 25 | $-1.4M | $-40.7M | ||
| Q1 25 | $15.3M | $-48.4M | ||
| Q4 24 | $5.1M | — | ||
| Q3 24 | $-11.1M | $-41.7M | ||
| Q2 24 | $-2.8M | $-80.3M | ||
| Q1 24 | $11.0M | $-53.5M |
毛利率EEXZLAB
| Q4 25 | — | 51.0% | ||
| Q3 25 | — | 59.5% | ||
| Q2 25 | — | 60.6% | ||
| Q1 25 | — | 63.6% | ||
| Q4 24 | — | 61.5% | ||
| Q3 24 | — | 64.1% | ||
| Q2 24 | — | 64.9% | ||
| Q1 24 | — | 61.4% |
营业利润率EEXZLAB
| Q4 25 | -11.8% | -54.6% | ||
| Q3 25 | -10.1% | -42.3% | ||
| Q2 25 | 9.7% | -50.3% | ||
| Q1 25 | 24.2% | -53.3% | ||
| Q4 24 | 19.5% | -62.6% | ||
| Q3 24 | -6.5% | -66.6% | ||
| Q2 24 | 7.4% | -76.0% | ||
| Q1 24 | 18.2% | -80.7% |
净利率EEXZLAB
| Q4 25 | -22.8% | — | ||
| Q3 25 | -18.6% | -31.2% | ||
| Q2 25 | -1.3% | -37.3% | ||
| Q1 25 | 10.4% | -45.8% | ||
| Q4 24 | 4.8% | — | ||
| Q3 24 | -15.3% | -40.9% | ||
| Q2 24 | -3.3% | -80.2% | ||
| Q1 24 | 8.2% | -61.4% |
每股收益（稀释后）EEXZLAB
| Q4 25 | $-0.15 | $-0.05 | ||
| Q3 25 | $-0.07 | $-0.03 | ||
| Q2 25 | $-0.01 | $-0.04 | ||
| Q1 25 | $0.08 | $-0.04 | ||
| Q4 24 | $0.01 | $-0.09 | ||
| Q3 24 | $-0.05 | $-0.04 | ||
| Q2 24 | $-0.03 | $-0.08 | ||
| Q1 24 | $0.00 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $100.9M | $689.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $338.8M | $715.5M |
| 总资产 | $1.2B | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资EEXZLAB
| Q4 25 | $100.9M | $689.6M | ||
| Q3 25 | $95.4M | $717.2M | ||
| Q2 25 | $156.4M | $732.2M | ||
| Q1 25 | $276.8M | $757.3M | ||
| Q4 24 | $194.8M | $779.7M | ||
| Q3 24 | $188.9M | $616.1M | ||
| Q2 24 | $193.2M | $630.0M | ||
| Q1 24 | $186.8M | $650.8M |
股东权益EEXZLAB
| Q4 25 | $338.8M | $715.5M | ||
| Q3 25 | $369.5M | $759.9M | ||
| Q2 25 | $389.4M | $791.7M | ||
| Q1 25 | $392.1M | $810.8M | ||
| Q4 24 | $385.9M | $840.9M | ||
| Q3 24 | $391.1M | $667.7M | ||
| Q2 24 | $407.6M | $704.2M | ||
| Q1 24 | $-90.7M | $762.2M |
总资产EEXZLAB
| Q4 25 | $1.2B | $1.2B | ||
| Q3 25 | $1.2B | $1.2B | ||
| Q2 25 | $1.2B | $1.2B | ||
| Q1 25 | $1.2B | $1.2B | ||
| Q4 24 | $1.0B | $1.2B | ||
| Q3 24 | $1.1B | $985.3M | ||
| Q2 24 | $1.1B | $987.4M | ||
| Q1 24 | $1.1B | $988.4M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $12.3M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $11.7M | $-26.7M |
| 自由现金流率自由现金流/营收 | 8.8% | -21.0% |
| 资本支出强度资本支出/营收 | 0.5% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $41.4M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流EEXZLAB
| Q4 25 | $12.3M | $-26.0M | ||
| Q3 25 | $1.8M | $-32.0M | ||
| Q2 25 | $15.9M | $-31.0M | ||
| Q1 25 | $12.6M | $-61.7M | ||
| Q4 24 | $20.6M | $-55.8M | ||
| Q3 24 | $9.1M | $-26.8M | ||
| Q2 24 | $9.8M | $-42.2M | ||
| Q1 24 | $7.3M | $-90.1M |
自由现金流EEXZLAB
| Q4 25 | $11.7M | $-26.7M | ||
| Q3 25 | $1.5M | $-35.0M | ||
| Q2 25 | $15.8M | $-33.9M | ||
| Q1 25 | $12.4M | $-63.2M | ||
| Q4 24 | $19.9M | $-58.4M | ||
| Q3 24 | $9.0M | $-28.2M | ||
| Q2 24 | $9.6M | $-42.9M | ||
| Q1 24 | $7.0M | $-91.1M |
自由现金流率EEXZLAB
| Q4 25 | 8.8% | -21.0% | ||
| Q3 25 | 1.9% | -30.4% | ||
| Q2 25 | 15.0% | -31.1% | ||
| Q1 25 | 8.4% | -59.9% | ||
| Q4 24 | 18.6% | -53.8% | ||
| Q3 24 | 12.4% | -27.7% | ||
| Q2 24 | 11.2% | -42.9% | ||
| Q1 24 | 5.2% | -104.5% |
资本支出强度EEXZLAB
| Q4 25 | 0.5% | 0.5% | ||
| Q3 25 | 0.4% | 2.6% | ||
| Q2 25 | 0.1% | 2.6% | ||
| Q1 25 | 0.1% | 1.5% | ||
| Q4 24 | 0.7% | 2.4% | ||
| Q3 24 | 0.1% | 1.3% | ||
| Q2 24 | 0.2% | 0.7% | ||
| Q1 24 | 0.2% | 1.1% |
现金转化率EEXZLAB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.82× | — | ||
| Q4 24 | 4.04× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.66× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EEX
| Connections Segment | $121.9M | 92% |
| Commerce Segment | $5.5M | 4% |
| Content | $5.3M | 4% |
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
